NLRP3 and Hepatic fibrosis: Also, in a bile duct ligation (BDL) model for cholestasis, MCC950 has been demonstrated to reduce liver fibrosis through inhibiting NLRP3 and the mechanism was partially attributed to inhibition of Toll-like receptor signaling (11).